v3.26.1
Note 7 - Segment Reporting - Reconciliation of Segment Operations (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
General and administrative $ 1,748,239 $ 1,429,299
Other income 31,748 4,771
Realized and unrealized gain (loss) 541 (80)
Net loss (4,461,895) (3,964,601)
Operating Segments [Member]    
Revenues 0 0
Clinical and regulatory 1,690,402 1,706,705
Manufacturing 612,212 483,065
Research 408,834 308,327
General and administrative 1,664,101 1,286,422
Non-cash expenses(1) [1],[2] 118,635 184,773
Other income 31,748 4,771
Realized and unrealized gain (loss) 541 (80)
Net loss $ 4,461,895 $ 3,964,601
[1] Includes $19,553 and $420,226 of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence
[2] Includes $230,861 and $184,773 of stock-based compensation expense for the three months ended March 31, 2026 and 2025.